Cancer Gene Therapy Market By Type, and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Share, Trends, Growth, Historical Developments, Current Trends, and Forecasts, 2021–2030

The Global Cancer Gene Therapy Market was valued at USD 558.24 million in 2019 and is estimated to reach USD 921.8 million by 2030, expanding at a CAGR of 32.6% during the forecast period, from 2020 to 2030.

Cancer gene therapy refers to the cancer treatment where therapeutic DNA is being introduced into the gene of the patient having cancer. The most commonly used technique for cancer gene therapy is replacing a mutated gene causing cancer with a healthy copy of the gene. Another technique used is the inactivation of a gene that is not functioning well. Lately, a new technique has been introduced to the cancer gene therapy market that is the insertion of new genes into the body which will help in fighting against the cancer cells. Due to its success rate in preclinical as well as clinical trial stages, cancer gene therapy is gaining recognition all over the world.

Key Growth Factors

The major factors such as the growing incidences of cancer population, favorable government initiatives, rising elderly population, and growing funds for research and development projects for cancer gene treatment are driving the growth of the global cancer gene therapy market. Other than this, ethical approval of cancer gene treatment and the rising recognition of DNA vaccines are propelling the global cancer gene therapy market over the forecast period. Furthermore, numerous cancer gene treatment products are in clinical trial phases. This, in turn, will continue to have a positive influence on the market. On the other hand, the available market in emergent countries, industrial developments leading to improved adoption, and ethical approval of cancer gene therapy treatment will create lucrative opportunities for the global market of cancer gene therapy market.

However, factors such as less awareness, high expenditure for cancer gene treatment, and unfavorable immune responses are likely to hamper the market growth of cancer gene therapy.

Regional Analysis

North America in terms of revenue is leading the global cancer gene therapy market, owing to the high geriatric population and industrial development in this region. Similarly, Europe is dominating the global market of cancer gene therapy. Moreover, the Asia-Pacific is likely to experience the highest growth in the cancer gene therapy market because of rising government programs, and growing cost-cutting measures and development in healthcare infrastructure. Also, other factors like the large population of patients, growing research and development investments, and increasing government funding in developing countries are responsible for market expansion.

Top Market Players

Some key market players in the global cancer gene therapy market include Vigene Biosciences, Cell Genesys, Sirion Biotech, Adaptimmune, Advantagene, Bluebird Bio, GenVec, Cobra, BioCancell, Cellectis, Sarepta Therapeutics, Epeius Biotechnologies, Uniqure, Introgen Therapeutics, ZIOPHARM Oncology, Finvector MultiVir, Shenzhen SiBiono GeneTech, GlaxoSmithKline, Merck, and Celgene.

Report Attribute Details
The market size value in 2019 USD 558.24 million
The revenue forecast in 2030 USD 921.8 million
Growth Rate CAGR of 32.6% from 2020 to 2030
The base year for estimation 2021
Historical data 2018 – 2020
Forecast period 2022 – 2030
Top Manufacturers Vigene Biosciences, Cell Genesys, Sirion Biotech, Adaptimmune, Advantagene, Bluebird Bio, GenVec, Cobra, BioCancell, Cellectis, Sarepta Therapeutics, Epeius Biotechnologies, Uniqure, Introgen Therapeutics, ZIOPHARM Oncology, Finvector MultiVir, Shenzhen SiBiono GeneTech, GlaxoSmithKline, Merck, and Celgene.
Product Types Ex-vivo, In-vivo
Application Types Viral Vectors, Non-viral Vectors, Others
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East and Africa

This report segments the global cancer gene therapy market as follows:

Global Cancer Gene Therapy Market: By Type

  • Ex-vivo
  • In-vivo

Global Cancer Gene Therapy Market: By Product

  • Viral Vectors
  • Non-viral Vectors
  • Others

Global Cancer Gene Therapy Market: Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

1. Preface
        1.1. Study Scope and Description
        1.2. Research Scope
        1.3. Research Methodology
                1.3.1. Market Research Process
                1.3.2. Market Research Methodology


2. Executive Summary
        2.1. Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
        2.2. Cancer Gene Therapy Market: Snapshot


3. Global Cancer Gene Therapy Market– Industry Analysis
        3.1. Cancer Gene Therapy Market: Market Dynamics
        3.2. Market Drivers
                3.2.1. Increasing incidences of cancer population
                3.2.2. Increasing funding for R&D projects for cancer gene treatment
        3.3. Market Restraints
                3.3.1. Restraint 1
                3.3.2. Restraint 2
        3.4. Market Opportunities
        3.5. Future Trends
        3.6. Porter’s Five Forces Analysis
        3.7. Market Attractiveness Analysis
                3.7.1. Market attractiveness analysis By Type
                3.7.2. Market attractiveness analysis By Product
                3.7.3. Market attractiveness analysis By Region


4. Global Cancer Gene Therapy Market– Competitive Landscape
        4.1. Company market share analysis
                4.1.1. Global Cancer Gene Therapy Market: company market share, 2021
        4.2. Strategic development
                4.2.1. Mergers & Acquisitions
                4.2.2. Latest Product launches
                4.2.3. Partnerships, collaborations, agreements, and joint ventures
                4.2.4. Research & development and Regional expansion
        4.3. Value trend analysis


5. Global Cancer Gene Therapy Market Synopsis – Type Analysis
        5.1. Global Cancer Gene Therapy Market overview: By Type
                5.1.1. Global Cancer Gene Therapy Market share, By Type, Revenue and Forecast 2022 and 2030
        5.2. Ex-vivo
                5.2.1. Global Cancer Gene Therapy Market by Ex-vivo, Revenue and Forecast 2018–2030 (USD Million)
        5.3. In-vivo
                5.3.1. Global Cancer Gene Therapy Market by In-vivo, Revenue and Forecast 2018–2030 (USD Million)


6. Global Cancer Gene Therapy Market Synopsis: By Product Analysis
        6.1. Global Cancer Gene Therapy Market overview: By Product
                6.1.1. Global Cancer Gene Therapy Market share, By Product, Revenue and Forecast 2022 and 2030
        6.2. Viral Vectors
                6.2.1. Global Cancer Gene Therapy Market by Viral Vectors, Revenue and Forecast 2018–2030 (USD Million)
        6.3. Non-viral Vectors
                6.3.1. Global Cancer Gene Therapy Market by Non-viral Vectors, Revenue and Forecast 2018–2030 (USD Million)
        6.4. Others
                6.4.1. Global Cancer Gene Therapy Market by Others, Revenue and Forecast 2018–2030 (USD Million)


7. Global Cancer Gene Therapy Market Synopsis - Regional Analysis
        7.1. Global Cancer Gene Therapy Market overview: by Region
                7.1.1. Global Cancer Gene Therapy Market share, by Region, Revenue and Forecast 2022 and 2030
        7.2. North America
                7.2.1. North America Cancer Gene Therapy Market, Revenue and Forecast 2018-2030 (USD Million)
                7.2.2. North America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.2.3. North America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.2.4. The U.S.
                        7.2.4.1. The U.S. Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.2.4.2. The U.S. Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.2.5. Rest of North America
                        7.2.5.1. Rest of North America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.2.5.2. Rest of North America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
        7.3. Europe
                7.3.1. Europe Cancer Gene Therapy Market, Revenue and Forecast 2018-2030 (USD Million)
                7.3.2. Europe Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.3.3. Europe Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.3.4. UK
                        7.3.4.1. U.K. Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.3.4.2. U.K. Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.3.5. France
                        7.3.5.1. France Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.3.5.2. France Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.3.6. Germany
                        7.3.6.1. Germany Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.3.6.2. Germany Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.3.7. Rest of Europe
                        7.3.7.1. Rest of Europe Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.3.7.2. Rest of Europe Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
        7.4. Asia Pacific
                7.4.1. Asia Pacific Cancer Gene Therapy Market, Revenue and Forecast 2018-2030 (USD Million)
                7.4.2. Asia Pacific Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.4.3. Asia Pacific Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.4.4. China
                        7.4.4.1. China Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.4.4.2. China Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.4.5. Japan
                        7.4.5.1. Japan Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.4.5.2. Japan Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.4.6. India
                        7.4.6.1. India Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.4.6.2. India Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.4.7. Rest of Asia Pacific
                        7.4.7.1. Rest of Asia Pacific Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.4.7.2. Rest of Asia Pacific Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
        7.5. Latin America
                7.5.1. Latin America Cancer Gene Therapy Market, Revenue and Forecast 2018-2030 (USD Million)
                7.5.2. Latin America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.5.3. Latin America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.5.4. Brazil
                        7.5.4.1. Brazil Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.5.4.2. Brazil Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.5.5. Rest of Latin America
                        7.5.5.1. Rest of Latin America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                        7.5.5.2. Rest of Latin America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
        7.6. The Middle East and Africa
                7.6.1. The Middle East and Africa Cancer Gene Therapy Market, Revenue and Forecast 2018-2030 (USD Million)
                7.6.2. The Middle East and Africa Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.6.3. The Middle East and Africa Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.6.4. Saudi Arabia Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.6.5. Saudi Arabia Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.6.6. UAE Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.6.7. UAE Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)
                7.6.8. The Rest of Middle East and Africa Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018-2030 (USD Million)
                7.6.9. The Rest of Middle East and Africa Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018-2030 (USD Million)

8. Company Profiles
        8.1. Vigene Biosciences
                8.1.1. Overview
                8.1.2. Financials Synopsis
                8.1.3. Product Portfolio
                8.1.4. Business Tactic
                8.1.5. Key Developments
        8.2. Cell Genesys
                8.2.1. Overview
                8.2.2. Financials Synopsis
                8.2.3. Product Portfolio
                8.2.4. Business Tactic
                8.2.5. Key Developments
        8.3. Sirion Biotech
                8.3.1. Overview
                8.3.2. Financials Synopsis
                8.3.3. Product Portfolio
                8.3.4. Business Tactic
                8.3.5. Key Developments
        8.4. Adaptimmune
                8.4.1. Overview
                8.4.2. Financials Synopsis
                8.4.3. Product Portfolio
                8.4.4. Business Tactic
                8.4.5. Key Developments
        8.5. Advantagene
                8.5.1. Overview
                8.5.2. Financials Synopsis
                8.5.3. Product Portfolio
                8.5.4. Business Tactic
                8.5.5. Key Developments
        8.6. Bluebird Bio
                8.6.1. Overview
                8.6.2. Financials Synopsis
                8.6.3. Product Portfolio
                8.6.4. Business Tactic
                8.6.5. Key Developments
        8.7. GenVec
                8.7.1. Overview
                8.7.2. Financials Synopsis
                8.7.3. Product Portfolio
                8.7.4. Business Tactic
                8.7.5. Key Developments
        8.8. Cobra
                8.8.1. Overview
                8.8.2. Financials Synopsis
                8.8.3. Product Portfolio
                8.8.4. Business Tactic
                8.8.5. Key Developments
        8.9. BioCancell
                8.9.1. Overview
                8.9.2. Financials Synopsis
                8.9.3. Product Portfolio
                8.9.4. Business Tactic
                8.9.5. Key Developments
        8.10. Cellectis
                8.10.1. Overview
                8.10.2. Financials Synopsis
                8.10.3. Product Portfolio
                8.10.4. Business Tactic
                8.10.5. Key Developments
        8.11. Sarepta Therapeutics
                8.11.1. Overview
                8.11.2. Financials Synopsis
                8.11.3. Product Portfolio
                8.11.4. Business Tactic
                8.11.5. Key Developments
        8.12. Epeius Biotechnologies
                8.12.1. Overview
                8.12.2. Financials Synopsis
                8.12.3. Product Portfolio
                8.12.4. Business Tactic
                8.12.5. Key Developments
        8.13. Uniqure
                8.13.1. Overview
                8.13.2. Financials Synopsis
                8.13.3. Product Portfolio
                8.13.4. Business Tactic
                8.13.5. Key Developments
        8.14. Introgen Therapeutics
                8.14.1. Overview
                8.14.2. Financials Synopsis
                8.14.3. Product Portfolio
                8.14.4. Business Tactic
                8.14.5. Key Developments
        8.15. ZIOPHARM Oncology
                8.15.1. Overview
                8.15.2. Financials Synopsis
                8.15.3. Product Portfolio
                8.15.4. Business Tactic
                8.15.5. Key Developments
        8.16. FinvectorMultiVir
                8.16.1. Overview
                8.16.2. Financials Synopsis
                8.16.3. Product Portfolio
                8.16.4. Business Tactic
                8.16.5. Key Developments
        8.17. Shenzhen SiBionoGeneTech
                8.17.1. Overview
                8.17.2. Financials Synopsis
                8.17.3. Product Portfolio
                8.17.4. Business Tactic
                8.17.5. Key Developments
        8.18. GlaxoSmithKline
                8.18.1. Overview
                8.18.2. Financials Synopsis
                8.18.3. Product Portfolio
                8.18.4. Business Tactic
                8.18.5. Key Developments
        8.19. Merck
                8.19.1. Overview
                8.19.2. Financials Synopsis
                8.19.3. Product Portfolio
                8.19.4. Business Tactic
                8.19.5. Key Developments
        8.20. Celgene
                8.20.1. Overview
                8.20.2. Financials Synopsis
                8.20.3. Product Portfolio
                8.20.4. Business Tactic
                8.20.5. Key Developments


9. Appendix

List of Figures

1. Market research overview
2. Market research methodology
3. Global Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
4. Porter’s Five Forces Analysis
5. Global Cancer Gene Therapy Market attractiveness, By Type
6. Global Cancer Gene Therapy Market attractiveness, By Product
7. Global Cancer Gene Therapy Market share by Type, Revenue and Forecast 2022 and 2030 (USD Million)
8. Global Cancer Gene Therapy Market by Ex-vivo, Revenue and Forecast 2018–2030 (USD Million)
9. Global Cancer Gene Therapy Market by In-vivo, Revenue and Forecast 2018–2030 (USD Million)
10. Global Cancer Gene Therapy Market share by Product, Revenue and Forecast 2022 and 2030 (USD Million)
11. Global Cancer Gene Therapy Market by Viral Vectors, Revenue and Forecast 2018–2030 (USD Million)
12. Global Cancer Gene Therapy Market by Non-viral Vectors, Revenue and Forecast 2018–2030 (USD Million)
13. Global Cancer Gene Therapy Market by Others, Revenue and Forecast 2018–2030 (USD Million)
14. Global Cancer Gene Therapy Market share, by Region, Revenue and Forecast 2022 and 2030
15. North America Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
16. Europe Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
17. Asia Pacific Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
18. Latin America Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)
19. The Middle East and Africa Cancer Gene Therapy Market, Revenue and Forecast 2018–2030 (USD Million)

List of Tables

1. Global Cancer Gene Therapy Market: snapshot
2. Drivers of the Cancer Gene Therapy Market: impact analysis
3. North America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
4. North America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
5. The U.S. Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
6. The U.S. Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
7. Rest of North America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
8. Rest of North America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
9. Europe Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
10. Europe Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
11. UK Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
12. UK Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
13. France Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
14. France Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
15. Germany Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
16. Germany Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
17. Rest of Europe Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
18. Rest of Europe Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
19. Asia Pacific Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
20. Asia Pacific Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
21. China Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
22. China Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
23. Japan Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
24. Japan Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
25. India Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
26. India Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
27. Rest of Asia Pacific Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
28. Rest of Asia Pacific Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
29. Latin America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
30. Latin America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
31. Brazil Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
32. Brazil Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
33. Rest of Latin America Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
34. Rest of Latin America Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
35. The Middle East and Africa Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
36. The Middle East and Africa Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
37. Saudi Arabia Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
38. Saudi Arabia Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
39. South Africa Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
40. South Africa Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)
41. Rest of the Middle East & Africa Cancer Gene Therapy Market, By Type, Revenue and Forecast 2018–2030 (USD Million)
42. Rest of the Middle East & Africa Cancer Gene Therapy Market, By Product, Revenue and Forecast 2018–2030 (USD Million)

Research Framework

Vertex Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources
  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers
Secondary sources
  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases

DATA ANALYSIS

Data Synthesis
  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights
Data Validation
  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts

REPORT WRITING

Qualitative
  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis
Quantitative
  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape

Frequently Asked Questions About This Report

Global market for cancer gene therapy valued at 558.24 million in 2019 and is set to cross 921.8 million by 2030, according to a new report published by Vertex Market Research

Vigene Biosciences, Cell Genesys, Sirion Biotech, Adaptimmune, Advantagene, Bluebird Bio, GenVec, Cobra, BioCancell, Cellectis, Sarepta Therapeutics, Epeius Biotechnologies, Uniqure, Introgen Therapeutics, ZIOPHARM Oncology, Finvector MultiVir, Shenzhen SiBiono GeneTech, GlaxoSmithKline, Merck, and Celgene.

North America holds highest share in 2022.

Cancer incidence is on the rise in both developed and developing economies, and people are becoming more aware of the possibility of receiving cutting-edge gene therapies as a result.

Up